Actively Recruiting
Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Complications (CLOJAK)
Led by University Hospital, Bordeaux · Updated on 2024-12-17
120
Participants Needed
11
Research Sites
128 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Myeloproliferative Neoplasms (MPN) are associated with an increased risk of thrombosis. Platelets, red blood cells (RBC), leukocytes and endothelial cells are involved in these complications. An association with the JAK2V617F allele burden assessed in leukocytes has also been suggested. In some patients the allele burden measured in platelets and red blood cells is higher than the one determined in leukocytes. Our project aims at associating the risk of thrombosis with the allele burden determined in the cell populations (platelets, red blood cells, granulocytes and endothelial cells) and identifying high-risk clonality profiles.
CONDITIONS
Official Title
Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Complications (CLOJAK)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient (age 2018 years)
- Inclusion at diagnosis or during the year following the diagnosis of PV or ET (2016 WHO criteria except bone marrow biopsy that is optional), before introduction of a cytoreductive treatment
- Patient carrying a JAK2V617F mutation
- Subject registered with a social security scheme
- Written informed consent obtained
- Acceptance of inclusion in the FIMBANK registry (specific consent form needed)
You will not qualify if you...
- ET or PV Patient not carrying a JAK2V617F mutation
- Patient with cytoreductive treatment (hydroxyurea, anagrelide, interferon, ruxolitinib or other chemotherapy) at the time of blood sampling
- Person under judicial safeguards, trustee or curatorship
- Person unable to give her consent
- Non-cooperative person
- Exclusion period after another clinical study or participation to another clinical study in the 30 days before inclusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
CHU d'Angers, Service Maladies du Sang
Angers, France, 49933
Actively Recruiting
2
CH de Bayonne, Service Hématologie Clinique
Bayonne, France, 64100
Actively Recruiting
3
CHU de Bordeaux, Service Médecine Interne et Maladies Infectieuses
Bordeaux, France, 33000
Actively Recruiting
4
Institut Bergonié, Service Hématologie Clinique
Bordeaux, France, 33000
Actively Recruiting
5
CHU de Brest, Service Hématologie Clinique
Brest, France, 29609
Actively Recruiting
6
CH de Dax, Service Hématologie Clinique
Dax, France, 40100
Actively Recruiting
7
CH de Libourne, Service Hématologie Clinique
Libourne, France, 33500
Actively Recruiting
8
CH de Mont de Marsan, Service Oncologie
Mont-de-Marsan, France, 40000
Actively Recruiting
9
CHU de Bordeaux, Service Hématologie Biologie
Pessac, France, 33604
Actively Recruiting
10
CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire
Pessac, France, 33604
Actively Recruiting
11
CHU de Bordeaux, Service Médecine Interne
Pessac, France, 33604
Not Yet Recruiting
Research Team
O
Olivier MANSIER
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here